We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App





Hospital System Remotely Monitors Fetal Health of Pregnant COVID-19 Patients

By HospiMedica International staff writers
Posted on 16 Feb 2021
A hospital system will enable real-time fetal and maternal heart rate monitoring and analysis of pregnant COVID-19 patients by midwives and obstetricians, limiting the amount of physical interaction to potentially reduce the risk of coronavirus exposure and spread.

Sheba Medical Center (Tel Aviv, Israel) has initiated a pilot to test both the HeraBEAT fetal heart rate monitor and the HeraCARE digital pregnancy monitoring platform from HeraMED Ltd. More...
(Netanya, Israel). Additionally, Sheba will also test the PulseNmore ES ultrasound system from PulseNmore Ltd. (Omer, Israel) that docks with the patient’s mobile phone to deliver high quality images which can be viewed live by the hospital physicians via a secure telemedicine platform.

Sheba will use the HeraBEAT smart pregnancy monitor in operational mode to enable telehealth-based services in the hospital’s dedicated pregnancy COVID-19 unit. Pregnant women who are admitted to the hospital’s COVID-19 unit require continuous monitoring. The HeraBEAT monitor will enable real-time fetal and maternal heart rate monitoring and analysis by Sheba’s midwives and obstetricians, limiting the amount of physical interaction to potentially reduce the risk of COVID-19 exposure and spread. Alongside HeraBEAT, Sheba will use the HeraCARE digital pregnancy monitoring platform that offers a set of connected, digital health tools optimized to provide comprehensive pregnancy health trend base analysis. HeraCARE will enable pregnancy management through simple to follow daily tasks that optimize user adherence, and integrated reminders and incentives.

Sheba will also provide its pregnant COVID-19 patients with the PulseNmore ES ultrasound system that is intended for remote scan of fetal heartbeats, movements and assessment of amniotic fluid from 14-weeks of gestation onward. Its handheld design will enable the patients to perform ultrasound by themselves, thereby limiting the need for visits by physicians and nursing staff. PulseNmore ES ultrasound system docks with the patient’s mobile phone to deliver high quality images that can be viewed live by the hospital physicians via a secure telemedicine platform. An intuitive app guides the user through every step of the scanning and connection process. Sophisticated image filtering software (image enhancement, speckle reduction and Time Gain Control) also enhances the image quality. The physician can see the performed scan in real-time and talk to the end-user. GAIN, DEPTH and FOCUS settings can be adjusted during the communication for optimized image quality.

“Our goal in the pilot starting in the antepartum COVID-19 unit is to enable the highest standard of maternal care and fetal monitoring while reducing the risk of COVID-19 exposure and spread,” said Dr. Avi Tsur, M.D., Director of the Sheba Women’s Health Innovation Centre. “In the next steps, our mission will be to leverage these cutting-edge technologies to provide our pregnant patients with premium Maternal-Fetal remote care wherever they are, at home or at work.”

Related Links:
Sheba Medical Center
HeraMED Ltd.
PulseNmore Ltd.



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
VTE Prevention System
Flowtron ACS900
New
Diagnostic Ultrasound System
DC-80A
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: New clinical guidance suggests treatments to prevent blood clots in CLTI patients after leg artery procedures (Photo courtesy of Shutterstock)

Stronger Blood Clot Prevention Measures Needed After Leg Artery Procedures in High-Risk Patients

Chronic limb-threatening ischemia (CLTI), the most severe form of peripheral artery disease (PAD), significantly reduces blood flow to the legs and feet. Despite undergoing lower limb revascularization... Read more

Surgical Techniques

view channel
Image: The milli-spinner can shrink blood clots without rupturing them (Photo courtesy of Andrew Brodhead/Stanford)

New Technology More Than Doubles Success Rate for Blood Clot Removal

In cases of ischemic stroke, where a blood clot obstructs oxygen supply to the brain, time is critical. The faster the clot is removed and blood flow restored, the more brain tissue can be saved, improving... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.